RE:Interesting perspective
It is a volatile, speculative, clinical-stage penny stock with periodic management conflicts.
They do seem to have the goods. And management conflicts affect companies of all sizes.
There's not enough total value for professional advisors to recommend it to their clients. Many of the retail investors that might stumble upon it on their own would not consider buying a speculative penny stock. When it's a small cap valued at about $1 billion with a share price between $4 and $5 it will look like a much safer bet to the same people - IMHO.